Nanobiotix receives first approval to start phase II/III

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe


Small but heading for the big time

Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe

PARIS, Oct. 16, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205 ) , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS).

Patients with locally advanced STS have very limited therapeutic options. Today, a standard treatment of care before surgery is radiotherapy aiming to reduce the tumor volume. Thereafter surgery is still required to remove the tumor. But despite of radiotherapy, a considerable proportion of patients with advanced tumors that cannot be resected in their entirety. The remaining tumor mass promotes the further development of the disease resulting in a poor prognosis for the patient.

NBTXR3 has the potential to provide a significant clinical benefit by improving radiotherapy efficacy, destroying locally advanced tumors more efficiently and to improve the quality of surgery enabling a more complete removal of the tumor.

This international multi-center pivotal study will start in France and then be conducted in around 25-30 sites throughout Europe once further authorizations are received. This pivotal trial is expected to be the final step before registration in Europe (CE mark) and should be --completed towards the end of 2016. In the Asia-Pacific region, as announced recently, PharmaEngine intends to participate in this pivotal study by opening clinical sites in several countries.

In parallel, Nanobiotix is establishing industrialization, market access and reimbursement strategies for NBTXR3 to prepare for a potential product launch at the end of 2016.

Laurent Levy, CEO of Nanobiotix commented: "Following the ASCO results, this approval is the second most important step we have accomplished this year as it launches the last clinical phase before potential market authorization. We believe our product, NBTXR3 will offer meaningful clinical benefit for patients with advanced sarcomas where there are serious unmet medical needs."

-Ends-

Notes to Editors

About the Phase II/III registration Trial of NBTXR3 in STS

A multi-center randomized, open-label, two-arm Phase II/III trial in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. Patients in the experimental treatment arm (Arm A) will receive an intratumoral injection of NBTXR3 followed by radiotherapy and surgery. Patients in the control arm (Arm B) will be treated with radiotherapy alone followed by surgery only. It is expected to enroll approximately 180 patients to have 78 evaluable patients in each arm.

 

Study design

The primary objective of this study is to increase the pathological complete response rate (pCR) of intratumoral injection of NBTXR3 activated by external beam radiation therapy (EBRT), versus EBRT alone in patients with locally advanced STS of the extremity and trunk wall.

Secondary objectives are to assess the safety profile of NBTXR3 activated by radiotherapy (incidence of early and late adverse events), to compare the objective response rate (ORR), tumor volume changes after NBTXR3 and carcinological resection rates, and to evaluate limb amputation rates.

Exploratory objectives are to assess the tumor response, to evaluate the time-to-local recurrence, Local Recurrence Rate (LRR) at 12 months and to evaluate the time-to-distant recurrence and Distant-Recurrence Rate (DRR) at 12 months.

Based on the results of the Phase I pilot trial, the recommended NBTXR3 volume for the pivotal study is equivalent to 10% of the tumor volume. Hence, the injected amount of NBTXR3 will be based on each patient's tumor volume as determined by MRI.

An interim efficacy analysis will be performed once two-thirds of patients have been recruited, it is expected mid 2016. An Independent Data Monitoring Committee (IDMC) will be in charge of the reviewing the formal statistical interim analysis, to ensure the safety of all patients enrolled in the study, the quality of the data collected and the continued scientific validity of the study design.

About clinical trials in Europe

In Europe clinical development of a new medical device is normally conducted in two phases, pilot and pivotal studies, which is supposed to lead to the European CE marking from the Healthcare Regulatory Agencies.

Usually, in the pilot phase, the goal is to establish medical device safety and to assist in design of the pivotal trial. Medical device pilot or feasibility studies are generally limited to a small cohort of patients at one or two sites.

After establishing that the medical device is safe in this pilot group of patients, the pivotal trial is conducted to generate data to demonstrate that the medical device is safe and effective, for a defined intended use, within a certain patient population.

For the record, NBTXR3 has been classified in the EU as class III medical device. In the US, it has been classified as a drug by the Food and Drug Administration (FDA).

About NBTXR3 in Soft Tissue Sarcoma (STS)

STS are cancers arising from different types of tissues such as fat cells, muscles, joint structures and small vessels etc. In resectable cases, surgery is the only potentially curative treatment and constitutes the basis to achieve prolonged survival.

Nevertheless, a considerable proportion of patients present with locally advanced primary or relapsed tumors and cannot be resected with clean margins. These patients with big tumors are threatened with amputation for complete tumor removal. Progress of surgical techniques and the use of pre-operative radiotherapy have improved the disease outcome. However local and distant failures are frequently observed. 

There is strong evidence (scientific literature) that supports the importance of local control of tumor in patients with locally advanced STS. Indeed, achieving local control in these patients presenting with locally advanced disease is a determinant factor to improve disease free survival and overall survival. This is not surprising. Similar outcome is observed for other cancers.

Patients with high risk STS have few therapeutic options. Innovative treatments aimed at optimizing cancer cell killing and the surgical feasibility are needed.

NBTXR3 is the first product of the NanoXray portfolio to reach clinical development. The product comprises nanoparticles which can be injected directly into cancer cells.

Treatment with NBTXR3 nanoparticles and radiotherapy in locally advanced STS aims to destroy tumors more efficiently, to facilitate surgery and enable complete malignant tissue extraction during surgery.

NBTXR3 is a selective radioenhancer. The injected nanoparticles penetrate tumor cells and when exposed to radiotherapy make feasible the deposition of a high energy dose within the cancer cell, increasing cell killing and thus improving resectability and disease outcome.

Potential indications for this product include soft tissue sarcoma, head and neck cancer, liver cancer, glioblastoma (a specific form of brain cancer), rectal and prostate cancer.

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers (Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, H&N cancer, Glioblastoma, Prostate) via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Contact

Nanobiotix   Financial communication and investors relations
 

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com
 

New Cap
Emmanuel Huynh/ Louis-Victor Delouvrier
 +33 (0)1 44 71 98 53
nano@newcap.fr

 
Media relations
 

France - New Cap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr
   

Outside France - Instinctif Partners
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020
nanobiotix@instinctif.com

Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business.. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the 2013 financial annual report of Nanobiotix (a copy of which is available on www.nanobiotix.com ) and to developments in general economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.

Press release (PDF) http://hugin.info/157012/R/1863363/653858.pdf

HUG#1863363

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 101

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 58

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 113

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 43

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 124

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies

Updated Category News Views 313

VICTOR Pet Food Launches New Line for Sensitive Dogs and Puppies VICTOR Super Premium Pet Food, known for its dedication to high-quality pet nutrition, is proud to unveil a new line aimed specifically at canines with sensitive skin and stomach issues. The Sensitive Skin and Stomach line is designed to meet the dietary needs of both adult dogs and puppies, and will be...

Continue Reading
Exploring the Growth of the Pressure Monitoring Market

Updated Category News Views 181

The Expanding Pressure Monitoring Market This flourishing sector is gaining significant traction, reflecting a market valued at approximately US$13.63 billion in 2024, with a current rise to US$14.56 billion in 2025. The forecast indicates a notable compound annual growth rate (CAGR) of 8.3% from this point through 2032, culminating in an anticipated valuation of US$25.48...

Continue Reading
Citadel Credit Union Champions Community Engagement Initiatives

Updated Category News Views 636

Citadel Credit Union's Commitment to Community Support Citadel Credit Union is dedicated to reaffirming its commitment to its members and the surrounding region through an innovative approach to philanthropy. The organization has escalated its focus on community partnerships and employee-driven initiatives, making strides toward becoming a leader in promoting meaningful...

Continue Reading
TRIMEDX Bolsters Leadership with New Chief Data & AI Officer

Updated Category News Views 163

TRIMEDX Elevates Leadership with a Visionary Hire Indianapolis—TRIMEDX, a leading name in independent clinical asset management, is taking substantial strides in enhancing its technological offerings. The company has recently welcomed Srilekha Akula as its Chief Data & AI Officer. Her arrival marks a pivotal moment in TRIMEDX's journey, aimed at fostering innovation and...

Continue Reading
Exploring the Leadership of Ford as a Dividend Powerhouse

Updated Category News Views 170

Ford Motor Company (NYSE: F) has been a staple name in the automotive sector, but it’s got some serious hurdles to jump over. The stock price took a 12% nosedive over the past year, and while that might raise eyebrows, it also sets the stage for potential dividend plays. The price-to-earnings ratio is sitting pretty low at 11—sounds tempting for those looking at...

Continue Reading